Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrecizumab in experimental endotoxemia
NCT03083171Phase 1Completed
- Sponsor
- Adrenomed AG
- Start
- Jan 2017
- Primary completion
- May 2017
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adrecizumab in sepsis (4 arms), sponsored by Adrenomed AG. Primary endpoint: Safety and tolerability expressed in total number of treatment related (serious) adverse events at 3 months. Started Jan 2017; status: completed.
02
Drugs
adrecizumab
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT03083171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083171.